Viral infections are one of the main causes of asthma exacerbations. During the COVID-19 era, concerns regarding the relationship of SARS-CoV2 with asthma have been raised. The concerns are both for COVID severity and asthma exacerbations. Many studies on COVID-19 epidemiology and comorbidities have assessed whether asthma represents a risk factor for SARS-CoV2 infection and/or more severe course of the disease. This review covers the current evidence on the prevalence of asthma in COVID-19 and its association with susceptibility to and severity of SARS-CoV2 infection. It will examine the possible role of underlying asthma severity in COVID-19 related outcomes as well as the molecular mechanisms involved in the co-existence of these entities. The possible role of asthma inflammatory phenotypes will also be evaluated. Finally, the impact of asthma comorbidities and the implications of asthma medication on COVID-19 will be addressed.
【저자키워드】 COVID-19, immunology, Asthma, SARS-CoV2, asthma treatment, 【초록키워드】 Epidemiology, susceptibility, severity, Infection, Comorbidity, outcome, molecular mechanism, risk factor, SARS-CoV2 infection, COVID, Prevalence, association, Evidence, inflammatory phenotype, implication, Course, involved, the disease, evaluated, raised, cause, addressed, asthma medication, 【제목키워드】 relationship,